Summary Corcept Therapeutics Incorporated (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept received approval from the US FDA for its lead product candidate Korlym (mifepristone), which modulates the effect of cortisol by selectively blocking the binding of the GR receptor. Korlym is the first drug candidate to be approved for the treatment of patients with Cushing’s syndrome. Other products in the pipeline include mifepristone for psychotic depression; CORT 108297 and other GR antagonists that help in the prevention of antipsychotic-induced weight gain mitigation. Corcept is headquartered in California, the US. Corcept Therapeutics Incorporated (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity,... Research Beam Model: Research Beam Product ID: 714088 250 USD New
Corcept Therapeutics Incorporated (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Corcept Therapeutics Incorporated (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Healthcare
  • Published On : July   2016
  • Pages : 23
  • Publisher : GlobalData
 
 
 
Summary

Corcept Therapeutics Incorporated (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Corcept received approval from the US FDA for its lead product candidate Korlym (mifepristone), which modulates the effect of cortisol by selectively blocking the binding of the GR receptor. Korlym is the first drug candidate to be approved for the treatment of patients with Cushing’s syndrome. Other products in the pipeline include mifepristone for psychotic depression; CORT 108297 and other GR antagonists that help in the prevention of antipsychotic-induced weight gain mitigation. Corcept is headquartered in California, the US.

Corcept Therapeutics Incorporated (CORT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 10
Corcept Therapeutics Completes Public Offering Of Common Stock For US$46.4 Million 11
Corcept Therapeutics Completes Private Placement Of Shares For US$12.4 Million Upon Exercise Of Warrants 12
Corcept Therapeutics Completes An Underwritten Public Offering Of Its Common Stock For US$45 Million 13
Corcept Therapeutics Completes Public Offering Of US$15 Million 15
Corcept Therapeutics Raises US$7.1 Million Upon Exercise Of Warrants 17
Asset Transactions 18
Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To US$45 Million 18
Corcept Therapeutics Incorporated - Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
About GlobalData 23
Contact Us 23
Disclaimer 23
List Of Tables
List of Tables
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Corcept Therapeutics Incorporated, Deals By Therapy Area, 2010 to YTD 2016 8
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Corcept Therapeutics Raises USD17.2 Million in Private Placement of Shares upon Exercise of Warrants 10
Corcept Therapeutics Completes Public Offering Of Common Stock For US$46.4 Million 11
Corcept Therapeutics Completes Private Placement Of Shares For US$12.4 Million Upon Exercise Of Warrants 12
Corcept Therapeutics Completes An Underwritten Public Offering Of Its Common Stock For US$45 Million 13
Corcept Therapeutics Completes Public Offering Of US$15 Million 15
Corcept Therapeutics Raises US$7.1 Million Upon Exercise Of Warrants 17
Pharmakon Advisors Acquires Royalties Of Korlym From Corcept Therapeutics For Up To US$45 Million 18
Corcept Therapeutics Incorporated, Key Competitors 20
Corcept Therapeutics Incorporated, Key Employees 21
Lisst Of Figures
List of Figures
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Corcept Therapeutics Incorporated, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter